NewEdge Advisors’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-26
Closed -$196 – 3885
2024
Q1
$196 Hold
26
– – ﹤0.01% 3674
2023
Q4
$241 Buy
+26
New +$212 ﹤0.01% 3593
2023
Q1
– Sell
-21
Closed -$223 – 3734
2022
Q4
$223 Buy
+21
New +$203 ﹤0.01% 3290

Other funds holding HCAT

NewEdge Advisors's HCAT Position: Q2 2024 in Review

NewEdge Advisors sold out of Health Catalyst (HCAT) in Q2 2024, closing a stake of 26 shares — an estimated $196 sold.

NewEdge Advisors first reported a position in HCAT in Q4 2022 and held it in 3 quarters. The position peaked at $241 in Q4 2023. 161 funds tracked by Wall St. Rank hold HCAT as of Q2 2024.

  • NewEdge Advisors reported no remaining Health Catalyst position as of Q2 2024 after selling out during the quarter.
  • NewEdge Advisors sold 26 Health Catalyst shares in Q2 2024, an estimated $196.
  • NewEdge Advisors first reported a position in Health Catalyst in Q4 2022 and held it in 3 quarters.
  • NewEdge Advisors's Health Catalyst position peaked at $241 in Q4 2023.
  • 161 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2024.

Based on NewEdge Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.